SCHEMBL13627872

SCHEMBL13627872

Cc1ccc2c(c1)/C(=N/O)C(=O)N2Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.56
CA9 Q16790 2/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MAPT P10636 2/20 0.48
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PRKAB1 Q9Y478 1/20 0.43
HTT P42858 1/20 0.43
ACHE P22303 1/20 0.42
NLRP3 Q96P20 1/20 0.42
CA12 O43570 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
KCNN4 O15554 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627922 0.87 ACHE (0.48) HSP90AA1CA9CA1MAPTATM
SCHEMBL13627890 0.87 CA1 (0.53) HSP90AA1CA9CA1CA2MAPT
SCHEMBL13627876 0.86 CA9 (0.54) CA9CA1CA2MAPTATM
SCHEMBL13627923 0.85 UBE2N (0.52) HSP90AA1CA9CA1CA2MAPT
SCHEMBL13627917 0.84 ACHE (0.52) HSP90AA1CA9CA1CA2MAPT
SCHEMBL13627921 0.81 ACHE (0.58) HSP90AA1CA9CA1CA2MAPT
SCHEMBL13627948 0.81 TRPA1 (0.48) CA9CA1CA2MAPTATM
SCHEMBL13627919 0.79 ACHE (0.53) HSP90AA1CA9CA1CA2MAPT
SCHEMBL13627906 0.79 ALDH1A1 (0.52) CA9CA1CA2ATMACHE
SCHEMBL13627933 0.79 TP53 (0.53) CA9CA1CA2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 HSP90AA1 714/4885CA9 4713/4885CA1 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.